AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity

Diana Schnoegl; Angela Hiesinger; Nicholas D Huntington; Dagmar Gotthardt

doi:10.1016/j.coi.2023.102397

AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity

Curr Opin Immunol. 2023 Dec:85:102397. doi: 10.1016/j.coi.2023.102397. Epub 2023 Nov 4.

Authors

Diana Schnoegl¹, Angela Hiesinger², Nicholas D Huntington³, Dagmar Gotthardt⁴

Affiliations

¹ Institute for Rheumatology and Immunology, Medical University of Graz, Austria; Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
² Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
³ Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
⁴ Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria. Electronic address: dagmar.gotthardt@vetmeduni.ac.at.

PMID: 37931499
DOI: 10.1016/j.coi.2023.102397

Abstract

The proper functioning of cytotoxic lymphocytes, such as natural killer and CD8+ T cells, is essential for effective cancer-immunity and immunotherapy responses. The differentiation of these cells is controlled by several transcription factors (TFs), including members of the activator protein (AP)-1 family. The activity of AP-1 family members is regulated by various immune signaling pathways, which can be triggered by activating or inhibitory receptors as well as cytokines. The target genes controlled by AP-1 TFs are central to generate immunity to pathogens or malignancies. Here, we provide an overview of the current understanding of how AP-1 TFs regulate cytotoxic lymphocytes.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents*
CD8-Positive T-Lymphocytes
Cytokines / metabolism
Humans
Neoplasms*
T-Lymphocytes, Cytotoxic
Transcription Factor AP-1 / metabolism

Substances

Transcription Factor AP-1
Antineoplastic Agents
Cytokines